First Presumed West Nile Virus Patient in U.S. Responds to GenoMed`s Treatment
April 12, 2004 11:51:00 (ET)
ST. LOUIS, Apr 12, 2004 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (GMED, Trade), a Next Generation Disease Management(TM) company that uses its expertise in genes to improve patient outcomes, said today that its protocol has helped the first patient in the U.S. in 2004 who is presumed to have West Nile virus encephalitis. This patient represents the ninth success out of ten consecutive patients to be treated with GenoMed's protocol.
The patient is a 79-year-old male from Scioto County, Ohio who was admitted two weeks ago in a coma due to viral encephalitis. His antibody titers are still pending, but his case so far is consistent with West Nile virus encephalitis. Within 24 hours of starting GenoMed's treatment, the patient could move his fingers and toes when asked to do so. During the previous ten days he had lain unresponsive and paralyzed. Although it could be argued that he would have gotten better anyway, the speed of his improvement from a disease notorious for the slowness of any recovery, especially in the elderly, argues strongly for the effectiveness of GenoMed's treatment. Taken with similarly improbable recoveries in eight other patients, the evidence is mounting that GenoMed's protocol is curative.
West Nile virus is transmitted by mosquitoes and has proven fatal in outbreaks in the U.S., especially to the elderly. Most of the U.S., including California, is bracing for another outbreak of West Nile virus this year following an unseasonably warm spring.
GenoMed's patent-pending protocol uses blood-pressure drugs that are safe and already familiar to most physicians. They're carried in every drug store. The protocol, developed by Dr. David Moskowitz, the Company's Chairman, CEO and Chief Medical Officer, is based on the theory that brain inflammation and death result from an over-response by the patient's immune system to the West Nile virus. GenoMed's protocol specifically suppresses the immune system at an early step in its activation. It is the only treatment for West Nile virus encephalitis shown to have a 90 percent cure rate. The results of Dr. Moskowitz's first eight patients will be published soon in a peer-reviewed medical journal.
The only way to prove that GenoMed's treatment is effective in West Nile virus encephalitis is to try it in more people. GenoMed is therefore conducting a free, nationwide clinical trial for West Nile virus this summer. The Company would like to eliminate the threat of West Nile virus on the 50th anniversary of the famous 1954 polio field trials which ended the threat of polio in the U.S. For information, click on the "West Nile trial" button at genomedics.com .
Dr. Moskowitz is a Harvard- and Oxford-educated physician, who trained for seven years in Internal Medicine, Biochemistry, and Nephrology at Washington University School of Medicine in St. Louis before spending 11 years on the faculty of St. Louis University School of Medicine. He is a noted pioneer in the field of medical genomics, and has been recognized for his groundbreaking treatment of diseases associated with the angiotensin I-converting enzyme, such as chronic renal failure due to hypertension or type II diabetes. Dr. Moskowitz's research on viruses, including West Nile virus, avian influenza ("bird flu"), and SARS, are regarded as innovative approaches for otherwise incurable diseases.
About GenoMed |
